Will Oscar Health's bronze plan monthly churn rate remain below 2% through Q2 2026?
Current Prediction
Why This Question Matters
Bronze plans grew from 25% to 39% of Oscar's book — the largest mix shift. The Gravy Gauge flags higher deductible bronze plans as more churn-prone. If bronze monthly churn exceeds 2% (management's pre-ARPA benchmark), the revenue composition shift is destroying value. If churn stays below 2%, it validates that Oscar's product design and member experience can retain price-sensitive members even without enhanced subsidies.
Prediction Distribution
Individual Predictions(9 runs)
Management's pre-ARPA churn benchmark of 1-2% monthly is their stated expectation. The question is whether this benchmark holds for a population that has dramatically shifted toward bronze plans after the subsidy cliff. Bronze members are by definition more price-sensitive — they chose the lowest-cost option. When they start incurring healthcare costs (Q2, after deductibles start being met), they may exit. The 2% threshold is the upper end of the pre-ARPA range. Given the unprecedented subsidy cliff and bronze-heavy mix, I slightly lean toward churn exceeding 2%.
The 2% monthly threshold is the upper end of the pre-ARPA benchmark (1-2%). For bronze churn to stay below 2%, it needs to behave like pre-ARPA overall churn. But bronze members in a post-subsidy environment face a unique combination of higher premiums (no enhanced subsidies) and high deductibles. This is more stressful than pre-ARPA conditions. However, Oscar's innovative product design (lifestyle products, member experience) may create stickier relationships than traditional bronze plans. True coin-flip.
The key insight is that the 400K churn expected in Q1 removes the most price-sensitive members first — those who don't pay at all after the grace period. The members remaining in Q2 are those who actively chose to pay. This self-selection may mean the remaining bronze population is more committed than average. However, the CMS program integrity initiatives are reducing SEP re-enrollment, making churn one-directional. And Q2 is when healthcare utilization ramps, creating dissatisfaction with high-deductible plans. Slightly lean NO — churn may exceed 2%.
Bronze members in the post-subsidy environment face a double hit: higher premiums AND high deductibles. The grace period ending in Q1 will flush out non-payers, but the remaining members still face cost pressure throughout Q2. Monthly churn of 2% is the high end of the pre-ARPA benchmark — for an unprecedented subsidy cliff situation, exceeding this benchmark seems plausible. Slight lean NO.
Oscar's broker expansion (60%) and product innovation (lifestyle products) may create differentiation that reduces churn versus generic bronze plans. The company's AI-driven member experience (86% question completion, 67% response time reduction) could improve satisfaction and retention. Pre-ARPA churn was 1-2%, and the 2% threshold provides some buffer. However, this is genuinely uncertain. Slight lean YES given product differentiation.
The resolution criteria is somewhat ambiguous — Oscar may not explicitly disclose bronze-specific churn rates, in which case this market may be difficult to resolve. Setting that aside, the structural dynamics are negative for bronze retention: price-sensitive population, subsidy cliff, high deductibles, and Q2 utilization ramp. The analysis's concern about revenue quality from the bronze mix shift is well-founded. Lean NO.
Bronze members are price-sensitive. Post-subsidy conditions are tougher than pre-ARPA. But Oscar's products may help retention. Slight lean NO given structural headwinds.
Genuinely uncertain. The 2% threshold is at the upper end of pre-ARPA benchmarks. Post-subsidy conditions are worse but Oscar's products are better. True coin-flip with low confidence.
The combination of subsidy cliff impact, bronze price sensitivity, and Q2 utilization ramp creates headwinds for staying below 2% churn. The pre-ARPA benchmark may not apply in a more stressed environment. Lean NO.
Resolution Criteria
Resolves YES if Oscar Health discloses (in Q2 2026 earnings call, 10-Q, or investor presentation) that bronze plan monthly churn averaged below 2.0% for April-June 2026, or if total plan churn data implies bronze churn below this level. Resolves NO if bronze churn averaged 2.0% or above, or if management describes bronze churn as exceeding pre-ARPA benchmarks.
Resolution Source
Oscar Health Q2 2026 earnings release, 10-Q, or earnings call transcript
Source Trigger
Bronze plan churn rate — With bronze now 39% of the book (up from 25%), higher-than-expected bronze churn would signal adverse selection and revenue leakage
Full multi-lens equity analysis